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There are many unanswered questions regarding the
mechanisms of joint damage in the only real rheumatologic
emergency, septic arthritis. Aside from antibiotic therapy,
clinical studies in this area have shown that the single most
important element in the successful treatment of septic
arthritis is early adequate drainage of the joint [1]. For
joints, the outcome from septic arthritis is frequently poor,
with moderate to severe damage to the joint in more than a
third of patients, regardless of whether treatment was with
aspiration alone, or surgical. Progress in this field has been
hindered by a lack of knowledge concerning the mecha-
nism of destruction in the infected joint. Pus in the joints
can mediate chondrolysis, at least in part because of the
presence of numerous activated host leukocytes [2]. But
how does the presence of bacteria in the joint initiate the
inflammatory process? Our understanding of this process
has been essentially limited to vague notions of ‘evil
humors’ from the bacteria. The ‘evil humors’ cannot be
bacterial endotoxins, since septic arthritis from gram posi-
tive bacteria is at least as damaging to joints as that from
gram negative. What then could the ‘evil humors’ be, and
how does this inform us about the optimal management of
this potentially devastating condition?
A recent study from Deng et al at the University of
Göteborg in Sweden provides new insight into a previ-
ously overlooked potential etiologic factor in septic
arthritis [3]. These investigators showed that the mere
introduction of bacterial DNA into the knee joints of
mice triggered rapid and severe inflammatory arthritis
with an influx of monocytes and the production of intra-
articular tumor necrosis factor-a. Joint damage was inde-
pendent of B or T cells, suggesting that it involved
instead the activation of the more evolutionarily primitive
innate immune system.
At first glance, it may seem quite surprising that highly
purified bacterial DNA could trigger such profound
immune effects in the absence of infection, especially
since injection of vertebrate DNA into the joints had no
pro-inflammatory activity. However, in recent years it
has become clear that DNA serves not just as the genetic
material for encoding genes, but also can have direct
immunostimulatory effects (reviewed in [4]). In verte-
brate DNA, the combination of bases in which a cytosine
is followed by a guanine, termed a CpG dinucleotide
(the ‘p’ refers to the phosphate bond linking the C and
the G), occurs less frequently than would be predicted
assuming a random combination of all possible bases in
the genome. Moreover, when CpGs occur in vertebrate
genomes, the C is almost always modified by the addi-
tion of a methyl cap. In contrast, bacterial DNA generally
has the expected frequency of CpG dinucleotides that
are not methylated. This subtle structural difference in
the DNA of vertebrates and bacterial pathogens is appar-
ently used by our immune system as a ‘danger signal’
indicating the presence of infection. Indeed, recent
studies showed that immune recognition of this elegantly
simple unmethylated ‘CpG motif’ has evolved as a rela-
tively simple way for the immune system to detect the
presence of bacteria or other pathogens without neces-
sarily recognising the identity of the specific pathogen
[5]. CpG motifs in bacterial DNA or synthetic oligonu-
cleotides rapidly stimulate macrophages, dendritic cells,
B cells, and natural killer cells to become activated, to
secrete pro-inflammatory cytokines, and to initiate pro-
tective immune responses [6]. The molecular mecha-
nism of action of CpG DNA involves cell uptake,
followed by activation of intracellular mitogen- -activated
protein kinases and transcription factors, including
nuclear factor kB and activator protein-1 [7–9]. Intrigu-
ingly, antimalarials such as chloroquine and quinacrine
have been found to specifically block all of the pro-
inflammatory effects of CpG at very low concentrations
that do not inhibit responses to other microbial sub-
stances, such as endotoxins [9–11]. CpG DNA can be
used therapeutically as a vaccine adjuvant against infec-
tious diseases, cancer, or allergy, or as a broad spectrumArthritis Research    Vol 1 No 1 Krieg
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immunotherapy. As would be expected for an immune
defense mechanism, Deng et al have shown that injec-
tion of CpG DNA systemically into mice had no adverse
effects on the joints. It is only when the CpG DNA (or
the infection) actually enters the joint that the pro-
inflammatory effects of CpG DNA appear to trigger
harmful inflammatory responses as opposed to protective
responses. On the other hand, CpG motifs present in
chlamydia DNA can act as adjuvants to trigger immune
responses to self antigens, causing heart disease [12].
Limitations of the present study include the fact that it is
not a realistic model of septic arthritis, and that the
inflammation resolves spontaneously if the injection of
CpG DNA into the joint is not repeated. In addition, it
seems intuitively likely that there is not just a single
trigger for joint damage in infected joints, but that this
must be the result of a complex interaction between mul-
tiple microbial signals and the host’s responses. Of
course, results in mice cannot always be extrapolated to
humans, though recent studies have shown that CpG
DNA activates human immune cells in a similar fashion
to those of mice [6].
These new findings provide an insight into what must
happen early in the course of septic arthritis. When bacteria
begin multiplying in a joint, the products of the bacteria
such as the CpG DNA will activate inflammatory host
defense mechanisms to control the infection and destroy the
invading bacteria even at the expense of causing permanent
joint damage. The CpG DNA is not toxic in and of itself,
but only because of its stimulatory effect on host immune
mechanisms. This understanding has important potential
implications for rheumatologic care. This model would cer-
tainly reinforce the need for early recognition and treatment
of septic arthritis. However, it also suggests the possibility
that joint aspiration alone may not be the optimal therapy for
septic arthritis, and that more aggressive closed joint lavage
may result in improved outcomes. This question seems
apposite as a subject for future clinical investigations.
It has long been suspected that unidentified chronic
microbial infection may underlie at least some cases of
chronic inflammatory arthritis. Several groups have
reported the presence of DNA from chlamydia and other
bacteria in joints of patients with inflammatory arthritis,
particularly reactive [13,14] (reviewed in [15]). These data
are of particular interest given the association of chlamydia
with autoimmune heart disease [12]. If these findings are
confirmed, the presence of CpG DNA in inflammatory
arthritic joints would finally provide a rationale for the
therapeutic use of antimalarials, which specifically block
CpG-induced inflammation [9–11]. Moreover, the identi-
fication of more potent small molecule inhibitors of CpG
DNA [16] may offer interesting new therapeutic options
for the treatment of inflammatory arthritis. Thus, DNA is
more than the key to the genetic blueprint, it may also
help to unlock a better understanding of infectious and
reactive arthritis.
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